Home › Trials › NCT07597018
Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 64

Two versions of cagrilintide in adults with overweight or obesity

Official title: Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or Obesity

Run by Novo Nordisk A/S · NCT07597018 · Data updated 2026-11-12

This study tests two versions of the drug cagrilintide to see how their blood levels compare in adults who are overweight or obese.

More Obesity trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 64 Years
SexAll
Enrollment234 (estimated)
SponsorNovo Nordisk A/S
Industry-sponsored
Locations1 site (Berlin)
StatusRecruiting
StartedMay 18, 2026
Main results expectedMay 28, 2027
Study endsJune 1, 2027
Registry record updatedJune 26, 2026
Trial IDNCT07597018 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-64 with BMI 27.0–34.9 kg/m2 who are generally healthy and have not previously participated in amylin-analogue studies.

Probably not a fit

Participants who do not show favorable pharmacokinetic profiles or have safety concerns may not benefit from the study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 trial compares two versions of cagrilintide (version D and version B) to see how they behave in the body after multiple doses. Participants are randomly assigned to receive either version D, version B, or placebo semaglutide I for about six months. The study focuses on safety and pharmacokinetics in generally healthy adults with BMI 27.0–34.9 kg/m2. Primary data will come from blood measurements and routine safety assessments.

Why it matters

Potential benefit: If successful, the findings could clarify how different versions of cagrilintide behave in the body and inform future dose selection.

How similar studies have gone: Other studies in this class of drugs have shown measurable differences in blood levels with different versions, supporting the approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Aged 18-64 years (both inclusive) at the time of signing informed consent
* Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria:

* Previous participation in study(s) with an amylin analogue. Participation is defined as randomisation.
* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

Where it's running

  • Parexel International GmbH
    Berlin, Germany     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Obesity 1426Overweight 159Novo Nordisk A/S 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.